Results 91 to 100 of about 231,281 (308)

Dose COVID-19 Uncovered a New Feature of Metronidazole Drug?Dose COVID-19 Uncover a New Feature of Metronidazole Drug?

, 2020
Studies of coronavirus disease 2019 (COVID-19) as a current global health problem shown the initial plasma levels of most pro-inflammatory cytokines increased during the infection, which leads to patient countless complications.
Mehdi, Shafiee Ardestani, Mohammad, Seyedhamzeh, Fatemeh, Aliabadi, Hamed, Reyhanfard, Hamidreza, Pazoki-Toroudi, Bahareh, Farasati Far, Shahrzad, Javanshir   +6 more
core   +1 more source

What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms

Virology Journal, 2023
Background Coronavirus disease 19 (COVID-19) is the disease caused by SARS-CoV-2, a highly infectious member of the coronavirus family, which emerged in December 2019 in “Wuhan, China”.
Sawsan Aboul-Fotouh, Ahmed Nageh Mahmoud, Esraa M. Elnahas, Mohamed Z. Habib, Sahar M. Abdelraouf   +4 more
doaj   +1 more source

SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review

Biomedicines, 2022
Sex differences identified in the COVID-19 pandemic are necessary to study. It is essential to investigate the efficacy of the drugs in clinical trials for the treatment of COVID-19, and to analyse the sex-related beneficial and adverse effects.
Donatas Stakišaitis, Linas Kapočius, Angelija Valančiūtė, Ingrida Balnytė, Tomas Tamošuitis, Arūnas Vaitkevičius, Kęstutis Sužiedėlis, Daiva Urbonienė, Vacis Tatarūnas, Evelina Kilimaitė, Dovydas Gečys, Vaiva Lesauskaitė   +11 more
doaj   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy

, 2022
COVID-19 was declared a pandemic in March 2020. The knowledge of COVID-19 pathophysiology soon provided a strong rationale for the early use of both anti-inflammatory and antithrombotic drugs; however, its evidence was slowly and partially incorporated ...
Marco Cosentino, Veronica Vernocchi, Carlo Servo Florio Pagano, Franca Marino, Alberto Dallari, Antonio Palma, on behalf of IppocrateOrg Association Working Group for the Early Outpatient Treatment of COVID-19 on behalf of IppocrateOrg Association Working Group for the Early Outpatient Treatment of COVID-19, Stefano Martini, Fabio Burigana, Maria Antonietta Bàlzola, Barbara Allasino, Mauro Rango   +11 more
core   +1 more source

Review of COVID-19 treatment

Journal of Research in Pharmacy Practice, 2020
Many contagious diseases, such as plague or cholera, played a role in changing the pathway of history. In this respect, although coronavirus was not as dangerous as novel diseases such as swine flu and Ebola, the spread and the power of coronavirus ...
Somayeh Sadeghi, Mahnaz Momenzadeh, Peiman Nasri, Mina Nickpour   +3 more
doaj   +1 more source

Where are we with drug treatments for covid-19? [PDF]

BMJ, 2021
A year since the pandemic began, just a handful of lifesaving drugs have emerged as approved covid-19 treatments.
openaire   +2 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

The Pharmacist’s Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications

Pharmacy, 2022
The global burden of the COVID-19 pandemic has not only disrupted healthcare delivery but has also compromised patients’ access to healthcare on account of the scarcity of medications and trained healthcare professionals.
Mohammed Salim Karattuthodi, Shabeer Ali Thorakkattil, Suhaj Abdulsalim, Sathvik Belagodu Sridhar, Sainul Abideen Parakkal, Savera Arain, Hafees Madathil, Ajmal Karumbaru Kuzhiyil, Mamdouh Mohammed Ahmed Ageeli, Mazhuvanchery Kesavan Unnikrishnan   +9 more
doaj   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source